We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

244 hedge funds and large institutions have $5.2B invested in Apellis Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 96 increasing their positions, 83 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

46% more call options, than puts

Call options by funds: $81.6M | Put options by funds: $55.8M

20% more funds holding in top 10

Funds holding in top 10: 10 → 12 (+2)

16% more repeat investments, than reductions

Existing positions increased: 96 | Existing positions reduced: 83

2.12% more ownership

Funds ownership: 88.77% → 90.89% (+2.1%)

2% less funds holding

Funds holding: 250 → 244 (-6)

10% less first-time investments, than exits

New positions opened: 36 | Existing positions closed: 40

22% less capital invested

Capital invested by funds: $6.65B → $5.2B (-$1.45B)

Holders
244
Holders Change
-6
Holders Change %
-2.4%
% of All Funds
3.92%
Holding in Top 10
12
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+20%
% of All Funds
0.19%
New
36
Increased
96
Reduced
83
Closed
40
Calls
$81.6M
Puts
$55.8M
Net Calls
+$25.8M
Net Calls Change
+$45.2M

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$210M
2
JP Morgan Chase
JP Morgan Chase
New York
+$48.1M
3
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$36.6M
4
OCA
Octagon Capital Advisors
New York
+$34.8M
5
BlackRock
BlackRock
New York
+$32.8M

Top Sellers

Rank Fund Capital Flow
1
Viking Global Investors
Viking Global Investors
Connecticut
-$63.7M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$63.6M
3
APM
Avidity Partners Management
Texas
-$57.6M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$31.9M
5
DCM
Driehaus Capital Management
Illinois
-$29.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
PFM
251
Privium Fund Management
Netherlands
– -$6.06M -92,616 Closed
1832 Asset Management
252
1832 Asset Management
Ontario, Canada
– -$6.02M -88,100 Closed
IHAM
253
Integral Health Asset Management
New York
– -$4.78M -70,000 Closed
CM
254
Castleark Management
Illinois
– -$3.95M -57,890 Closed
PP
255
PDT Partners
New York
– -$2.56M -37,504 Closed
Simplex Trading
256
Simplex Trading
Illinois
– -$1.57M -29,627 Closed
DC
257
Diametric Capital
Massachusetts
– -$1.95M -28,586 Closed
EI
258
EAM Investors
California
– -$1.87M -27,355 Closed
EGI
259
EAM Global Investors
California
– -$1.86M -27,245 Closed
MAP
260
Moody Aldrich Partners
Massachusetts
– -$1.56M -22,880 Closed
CCIA
261
Campbell & Co Investment Adviser
Maryland
– -$1.17M -17,177 Closed
CSS
262
Cubist Systematic Strategies
Connecticut
– -$953K -13,951 Closed
SCM
263
Soleus Capital Management
Connecticut
– -$915K -13,400 Closed
PCM
264
Prelude Capital Management
New York
– -$771K -11,293 Closed
Allianz Asset Management
265
Allianz Asset Management
Germany
– -$751K -11,000 Closed
FRM
266
Fox Run Management
Connecticut
– -$739K -10,819 Closed
LFAS
267
Level Four Advisory Services
Texas
– -$698K -10,214 Closed
WG
268
Winton Group
United Kingdom
– -$493K -7,218 Closed
FCM
269
Frontier Capital Management
Massachusetts
– -$423K -6,193 Closed
WMSA
270
Weiss Multi-Strategy Advisers
New York
– -$357K -5,224 Closed
GAM
271
Gotham Asset Management
New York
– -$304K -4,458 Closed
Los Angeles Capital Management
272
Los Angeles Capital Management
California
– -$295K -4,314 Closed
Envestnet Asset Management
273
Envestnet Asset Management
Illinois
– -$280K -4,104 Closed
CAMG
274
CWA Asset Management Group
Florida
– -$273K -4,000 Closed
CIBC Asset Management
275
CIBC Asset Management
Ontario, Canada
– -$248K -3,633 Closed
8 9 10
11
12

APLS Hedge Fund Activity: Q4 2022 in Review

244 of the 6,224 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q4 2022, worth a combined $5.2B — down 22% from $6.65B a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of APLS and 36 opened new positions — a net loss of 4 holders — while 83 trimmed existing stakes and 96 added.

The largest buyer was Janus Henderson Group, adding an estimated $210M. The largest seller was Viking Global Investors, exiting entirely with an estimated $63.7M sold.

  • 244 institutional investors held Apellis Pharmaceuticals (APLS) as of Q4 2022, down from 250 in Q3 2022.
  • Funds reported $5.2B of Apellis Pharmaceuticals stock for Q4 2022, down 22% quarter-over-quarter.
  • 36 funds opened new Apellis Pharmaceuticals positions in Q4 2022 and 40 closed out, a net change of -4 holders.
  • The largest Apellis Pharmaceuticals buyer in Q4 2022 was Janus Henderson Group, an estimated $210M added.
  • The largest Apellis Pharmaceuticals seller in Q4 2022 was Viking Global Investors, an estimated $63.7M sold.

Based on aggregated 13F filings for Q4 2022.